Biblioteca Virtual em Saúde

Pesquisa | Influenza A (H1N1)

  • BIREME | OPAS | OMS logo
 

Histórico de pesquisa  ()

Sua seleção  ()

 0 documento(s) selecionado(s).

Refine sua pesquisa

Collapse All  Ocultar
Expand All  Mostrar
Áreas temáticas
Texto completo (677)
Idioma
Ano de publicação

Enviar por email

Você tem 0 documento(s) selecionado(s).

Nenhum documento selecionado

 
Resultados  1-12 de 789
1.

Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study.

Autor(es): Glatthaar-Saalmüller, Bernadette; Mair, Kerstin H; Saalmüller, Armin
Fonte: Influenza Other Respir Viruses;11(1): 85-92, 2017 Jan.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27542891
Resumo: AIM: Aspirin (acetylsalicylic acid) has been used for more than 115 years in medicine. Research exists to show that aspirin has antiviral effects in vitro, for example, by blocking influenza virus propagation via NF-κB inhibition when used at high concentrations and short-term incubation steps. The aim of this study was to confirm the antiviral activity of aspirin against influenza virus and further elucidate the activity of aspirin against other respiratory viruses. METHODS: Tests to (mais)
2.

The Superiority of IFN-λ as a Therapeutic Candidate to Control Acute Influenza Viral Lung Infection.

Autor(es): Kim, Sujin; Kim, Min-Ji; Kim, Chang-Hoon; Kang, Ju Wan; Shin, Ha Kyung; Kim, Dong-Young; Won, Tae-Bin; Han, Doo Hee; Rhee, Chae Seo; Yoon, Joo-Heon; Kim, Hyun Jik
Fonte: Am J Respir Cell Mol Biol;56(2): 202-212, 2017 Feb.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27632156
Resumo: Here, we studied the IFN-regulated innate immune response against influenza A virus (IAV) infection in the mouse lung and the therapeutic effect of IFN-λ2/3 in acute IAV lung infection. For viral infections, IAV (WS/33, H1N1, PR8 H1N1, H5N1) were inoculated into wild-type mice by intranasal delivery, and IAV mRNA level and viral titer were measured. To compare the antiviral effect of IFNs in vivo in the lung, neutralizing antibodies and recombinant IFNs were used. After intranasal inoc (mais)
3.

Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015-2016 season in Japan.

Autor(es): Hibino, Akinobu; Kondo, Hiroki; Masaki, Hironori; Tanabe, Yoshinari; Sato, Isamu; Takemae, Nobuhiro; Saito, Takehiko; Zaraket, Hassan; Saito, Reiko
Fonte: Virus Genes;53(1): 89-94, 2017 Feb.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27714496
Resumo: We report five cases of community- and hospital-acquired infections with oseltamivir- and peramivir-resistant A(H1N1)pdm09 viruses possessing the neuraminidase (NA) H275Y mutation during January-February 2016 in Japan. One case was hospitalized and was receiving oseltamivir for prophylaxis. The remaining four cases were not taking antiviral drugs at the time of sampling. These cases were geographically distant and epidemiologically unrelated. The five viruses showed ~300-fold rise in IC va (mais)
4.

Successful use of oseltamivir prophylaxis in managing a nosocomial outbreak of influenza A in a hematology and allogeneic stem cell transplant unit.

Autor(es): Yue, Mimi C; Collins, Joel T; Subramoniapillai, Elango; Kennedy, Glen A
Fonte: Asia Pac J Clin Oncol;13(1): 37-43, 2017 Feb.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27730741
Resumo: AIM: To describe a nosocomial outbreak of H1N1 influenza A in an inpatient hematology and allogeneic stem cell transplant unit and outcomes of universal oseltamivir prophylaxis. METHODS: Medical records of all patients admitted to the unit were reviewed to define the nosocomial outbreak, commencing 1 week prior to the index case until 4 weeks following institution of oseltamivir prophylaxis. Timelines for clinical symptoms, viral spread, management, patient outcomes and follow up testing we (mais)
5.

Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model.

Autor(es): Don, Еlena S; Emelyanova, Alexandra G; Yakovleva, Natalia N; Petrova, Nataliia V; Nikiforova, Marina V; Gorbunov, Evgeniy A; Tarasov, Sergey А; Morozov, Sergey G; Epstein, Оleg I
Fonte: J Med Virol;89(5): 759-766, 2017 May.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27769099
Resumo: The assessment of dose-response is an essential part of drug development in terms of the determination of a drug's effective dose, finding the safety endpoint, estimation of the pharmacokinetic profile, and even validation of drug activity, especially for therapeutic agents with a principally novel mechanism of action. Drugs based on released-active forms of antibodies are a good example of such a target. In this study, the efficacy of the antiviral drug Anaferon for children (released-acti (mais)
6.

CLEC5A-Mediated Enhancement of the Inflammatory Response in Myeloid Cells Contributes to Influenza Virus Pathogenicity In Vivo.

Autor(es): Teng, Ooiean; Chen, Szu-Ting; Hsu, Tsui-Ling; Sia, Sin Fun; Cole, Suzanne; Valkenburg, Sophie A; Hsu, Tzu-Yun; Zheng, Jian Teddy; Tu, Wenwei; Bruzzone, Roberto; Peiris, Joseph Sriyal Malik; Hsieh, Shie-Liang; Yen, Hui-Ling
Fonte: J Virol;91(1)2017 Jan 01.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27795434
Resumo: Human infections with influenza viruses exhibit mild to severe clinical outcomes as a result of complex virus-host interactions. Induction of inflammatory mediators via pattern recognition receptors may dictate subsequent host responses for pathogen clearance and tissue damage. We identified that human C-type lectin domain family 5 member A (CLEC5A) interacts with the hemagglutinin protein of influenza viruses expressed on lentiviral pseudoparticles through lectin screening. Silencing CLEC5 (mais)
Assunto(s): Glicoproteínas de Hemaglutininação de Vírus da Influenza/imunologia Vírus da Influenza A Subtipo H1N1/patogenicidade Vírus da Influenza A Subtipo H5N1/patogenicidade Lectinas Tipo C/imunologia Infecções por Orthomyxoviridae/imunologia Receptores de Superfície Celular/imunologia Animais Anticorpos/farmacologia Quimiocina CXCL10/genética Quimiocina CXCL10/imunologia Regulação da Expressão Gênica Glicoproteínas de Hemaglutininação de Vírus da Influenza/genética Interações Hospedeiro-Patógeno Humanos Vírus da Influenza A Subtipo H1N1/crescimento & desenvolvimento Vírus da Influenza A Subtipo H1N1/imunologia Vírus da Influenza A Subtipo H5N1/crescimento & desenvolvimento Vírus da Influenza A Subtipo H5N1/imunologia Interferon-alfa/genética Interferon-alfa/imunologia Lectinas Tipo C/antagonistas & inibidores Lectinas Tipo C/genética Lentivirus/genética Lentivirus/imunologia Pulmão/efeitos de drogas Pulmão/imunologia Pulmão/virologia Macrófagos/efeitos de drogas Macrófagos/imunologia Macrófagos/virologia Macrófagos Alveolares/efeitos de drogas Macrófagos Alveolares/imunologia Macrófagos Alveolares/virologia Camundongos Camundongos Endogâmicos C57BL Camundongos Knockout Infecções por Orthomyxoviridae/genética Infecções por Orthomyxoviridae/mortalidade Infecções por Orthomyxoviridae/virologia Cultura Primária de Células Ligação Proteica Isoformas de Proteínas/genética Isoformas de Proteínas/imunologia RNA Interferente Pequeno/genética RNA Interferente Pequeno/metabolismo Receptores de Superfície Celular/antagonistas & inibidores Receptores de Superfície Celular/genética Análise de Sobrevida Receptor 3 Toll-Like/genética Receptor 3 Toll-Like/imunologia Fator de Necrose Tumoral alfa/genética Fator de Necrose Tumoral alfa/imunologia
7.

The pharmacological management of severe influenza infection - 'existing and emerging therapies'.

Autor(es): Mc Mahon, Aisling; Martin-Loeches, Ignacio
Fonte: Expert Rev Clin Pharmacol;10(1): 81-95, 2017 Jan.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27797595
Resumo: INTRODUCTION: Over the last century several influenza outbreaks have traversed the globe, most recently the influenza A(H1N1) 2009 pandemic. On each occasion, a highly contagious, virulent pathogen has emerged, leading to significant morbidity and mortality amongst those affected. Areas covered: Early antiviral therapy and supportive care is the mainstay of treatment. Treatment should be started as soon as possible and not delayed for the results of diagnostic testing. Whilst oseltamivir is (mais)
8.

Amino Acids in Hemagglutinin Antigenic Site B Determine Antigenic and Receptor Binding Differences between A(H3N2)v and Ancestral Seasonal H3N2 Influenza Viruses.

Autor(es): Wang, Xiaoquan; Ilyushina, Natalia A; Lugovtsev, Vladimir Y; Bovin, Nicolai V; Couzens, Laura K; Gao, Jin; Donnelly, Raymond P; Eichelberger, Maryna C; Wan, Hongquan
Fonte: J Virol;91(2)2017 Jan 15.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27807224
Resumo: Influenza A H3N2 variant [A(H3N2)v] viruses, which have caused human infections in the United States in recent years, originated from human seasonal H3N2 viruses that were introduced into North American swine in the mid-1990s, but they are antigenically distinct from both the ancestral and current circulating H3N2 strains. A reference A(H3N2)v virus, A/Minnesota/11/2010 (MN/10), and a seasonal H3N2 strain, A/Beijing/32/1992 (BJ/92), were chosen to determine the molecular basis for the antig (mais)
9.

Influenza Virus Overcomes Cellular Blocks To Productively Replicate, Impacting Macrophage Function.

Autor(es): Marvin, Shauna A; Russier, Marion; Huerta, C Theodore; Russell, Charles J; Schultz-Cherry, Stacey
Fonte: J Virol;91(2)2017 Jan 15.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27807237
Resumo: Whether influenza virus replication in macrophages is productive or abortive has been a topic of debate. Utilizing a panel of 28 distinct human, avian, and swine influenza viruses, we found that only a small subset can overcome cellular blocks to productively replicate in murine and primary human macrophages. Murine macrophages have two cellular blocks. The first block is during viral entry, where virions with relatively acid-stable hemagglutinin (HA) proteins are rendered incapable of pH-i (mais)
10.

Antigenic characterization of H5N1 highly pathogenic avian influenza viruses isolated from poultry in India, 2006-2015.

Autor(es): Bhat, Sudipta; Nagarajan, Shanmugasundaram; Kumar, Manoj; Murugkar, Harshad V; Kalaiyarasu, Semmannan; Venkatesh, Govindarajulu; Tosh, Chakradhar
Fonte: Arch Virol;162(2): 487-494, 2017 Feb.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27812833
Resumo: Highly pathogenic avian influenza (HPAI) is a major health concern worldwide. In this study, we focused on antigenic analysis of HPAI H5N1 viruses isolated from poultry in India between 2006 and 2015 comprising 25 isolates from four phylogenetic clades 2.2 (1 isolate), 2.2.2.1 (1 isolate), 2.3.2.1a (17 isolates) and 2.3.2.1c (6 isolates). Seven H5N1 isolates from all four clades were selected for production of chicken antiserum, and antigenic analysis was carried out by hemagglutination inh (mais)
11.

Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.

Autor(es): Sokolova, Anastasiya S; Yarovaya, Оlga I; Baev, Dmitry S; Shernyukov, Аndrey V; Shtro, Anna A; Zarubaev, Vladimir V; Salakhutdinov, Nariman F
Fonte: Eur J Med Chem;127: 661-670, 2017 Feb 15.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27823881
Resumo: A series of camphor derived imines was synthesised and evaluated in vitro for antiviral activity. Theoretical evaluations of ADME properties were also carried out. Most of these compounds exhibited significant activity against the drug-resistant strains of influenza A virus. Especially, compounds 2 (SI = 632) and 3 (SI = 417) presented high inhibition against influenza subtypes A/Puerto Rico/8/34 and A/California/07/09 of H1N1pdm09. Analysis of the structure-activity relationship showe (mais)
12.

The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.

Autor(es): Tu, Véronique; Abed, Yacine; Barbeau, Xavier; Carbonneau, Julie; Fage, Clément; Lagüe, Patrick; Boivin, Guy
Fonte: Antiviral Res;137: 6-13, 2017 Jan.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27838351
Resumo: Emergence of pan neuraminidase inhibitor (NAI)-resistant variants constitutes a serious clinical concern. An influenza A(H1N1)pdm09 variant containing the I427T/Q313R neuraminidase (NA) substitutions was previously identified in a surveillance study. Although these changes are not part of the NA active site, the variant showed reduced susceptibility to many NAIs. In this study, we investigated the mechanism of resistance for the I427T/Q313R substitution and its impact on the NA enzyme and v (mais)
Resultados  1-12 de 789